{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+3+Acute+Kidney+Injury",
    "query": {
      "condition": "Stage 3 Acute Kidney Injury"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+3+Acute+Kidney+Injury&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T10:09:19.494Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06036758",
      "title": "VIDAS® NEPHROCLEAR Diagnostic Accuracy Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Kidney Injury",
        "Stage 2 Acute Kidney Injury",
        "Stage 3 Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "VIDAS® NEPHROCLEAR™ CCL14 Test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "BioMérieux",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 477,
      "start_date": "2023-07-17",
      "completion_date": "2023-12-28",
      "has_results": false,
      "last_update_posted_date": "2024-02-28",
      "last_synced_at": "2026-09-28T10:09:19.494Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Chicago, Illinois",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06036758"
    },
    {
      "nct_id": "NCT02474667",
      "title": "Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Delayed Graft Function"
      ],
      "interventions": [
        {
          "name": "ANG-3777",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Angion Biomedica Corp",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 253,
      "start_date": "2016-03",
      "completion_date": "2021-09",
      "has_results": false,
      "last_update_posted_date": "2021-06-03",
      "last_synced_at": "2026-09-28T10:09:19.494Z",
      "location_count": 30,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Sacramento, California + 24 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02474667"
    },
    {
      "nct_id": "NCT05815485",
      "title": "A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Azeliragon",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Medical Branch, Galveston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 144,
      "start_date": "2023-05-04",
      "completion_date": "2026-04",
      "has_results": false,
      "last_update_posted_date": "2025-03-03",
      "last_synced_at": "2026-09-28T10:09:19.494Z",
      "location_count": 3,
      "location_summary": "Chicago, Illinois • Ann Arbor, Michigan • Galveston, Texas",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Galveston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05815485"
    },
    {
      "nct_id": "NCT05746559",
      "title": "ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "CKD",
        "Cardiac Disease",
        "Cardiopulmonary Bypass"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ravulizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 555,
      "start_date": "2023-04-06",
      "completion_date": "2026-05-07",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-09-28T10:09:19.494Z",
      "location_count": 16,
      "location_summary": "Orange, California • San Francisco, California • Stanford, California + 13 more",
      "locations": [
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05746559"
    },
    {
      "nct_id": "NCT02467075",
      "title": "Double-Blind Placebo-Controlled CIN Trial",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "Iopamidol 300 (Contrast)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (Normal Saline)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2015-07",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2017-06-27",
      "last_synced_at": "2026-09-28T10:09:19.494Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02467075"
    },
    {
      "nct_id": "NCT02248051",
      "title": "Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Kidney Injury (Nontraumatic)"
      ],
      "interventions": [
        {
          "name": "CXA-10",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Complexa, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 12,
      "start_date": "2014-09",
      "completion_date": "2015-09",
      "has_results": false,
      "last_update_posted_date": "2018-02-01",
      "last_synced_at": "2026-09-28T10:09:19.494Z",
      "location_count": 2,
      "location_summary": "Anaheim, California • Kalamazoo, Michigan",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Kalamazoo",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02248051"
    },
    {
      "nct_id": "NCT06150742",
      "title": "Nafamostat Efficacy in Phase 3 Registrational CRRT Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "Niyad (nafamostat mesylate)",
          "type": "DEVICE"
        },
        {
          "name": "Placebo (0.9% NaCl)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Talphera, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 70,
      "start_date": "2024-08-15",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-09-28T10:09:19.494Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Orlando, Florida • Detroit, Michigan + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        },
        {
          "city": "Great Neck",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06150742"
    },
    {
      "nct_id": "NCT03510897",
      "title": "QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cardiac Surgery"
      ],
      "interventions": [
        {
          "name": "teprasiran",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Quark Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1043,
      "start_date": "2018-06-29",
      "completion_date": "2021-04-12",
      "has_results": false,
      "last_update_posted_date": "2021-07-16",
      "last_synced_at": "2026-09-28T10:09:19.494Z",
      "location_count": 36,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03510897"
    },
    {
      "nct_id": "NCT03119662",
      "title": "A Study to Explore the Renal Safety of Visipaque Injection 320 mgI/mL in Patients With Chronic Kidney Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Kidney Diseases"
      ],
      "interventions": [
        {
          "name": "Visipaque",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GE Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2018-02-08",
      "completion_date": "2018-10-19",
      "has_results": true,
      "last_update_posted_date": "2019-12-17",
      "last_synced_at": "2026-09-28T10:09:19.494Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Mesa, Arizona • Little Rock, Arkansas + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Doral",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03119662"
    },
    {
      "nct_id": "NCT04411472",
      "title": "(Revival) Study to Investigate the Efficacy and Safety of Alkaline Phosphatase in Patients With Sepsis-Associated AKI",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Kidney Injury Due to Sepsis"
      ],
      "interventions": [
        {
          "name": "Recombinant human alkaline phosphatase",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "AM-Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 676,
      "start_date": "2020-11-02",
      "completion_date": "2022-08-18",
      "has_results": true,
      "last_update_posted_date": "2024-06-03",
      "last_synced_at": "2026-09-28T10:09:19.494Z",
      "location_count": 16,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 12 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Glenview",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04411472"
    }
  ]
}